Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Antisense Therapeutics Ltd.

Headquarters: Toorak, Victoria, Australia
Year Founded: 2000
Status: Public
Industry Sector: HealthTechnology
CEO: James Stuart Garner, PhD, MBA
Number Of Employees: N/A
Enterprise Value: $25,474,073
PE Ratio: -0.58
Exchange/Ticker 1: ASX:ANP
Exchange/Ticker 2: N/A
Latest Market Cap: $6,536,117

BioCentury | Aug 26, 2022
Discovery & Translation

Detecting Parkinson’s via breathing signals; plus Antisense, Noster and more

BioCentury’s roundup of translational news
BioCentury | Jun 5, 2021
Targets & Mechanisms

Going beyond genetic medicines for muscular dystrophy

Muscular dystrophy programs in the clinic cover not only a range of muscle mechanisms but also anti-fibrotic and anti-inflammation ones
BioCentury | Nov 16, 2015
Regulation

Scaling compassion

FDA, industry, patient groups charting compassionate use policies
BioCentury | May 25, 2015
Company News

Antisense Therapeutics, Cortendo deal

BioCentury | Oct 6, 2014
Financial News

Antisense Therapeutics completes private placement

BioCentury | Oct 6, 2014
Financial News

Antisense Therapeutics proposes private placement

BioCentury | Sep 8, 2014
Clinical News

ATL1103: Additional Phase II data

BioCentury | Sep 8, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones
BioCentury | Sep 4, 2014
Clinical News

Antisense reports acromegaly data

BioCentury | Mar 31, 2014
Clinical News

ATL1102: Phase I started

Items per page:
1 - 10 of 30